A targeted cytotoxic somatostatin (SST) analogue, AN-238, inhibits the growth of H-69 small-cell lung carcinoma (SCLC) and H-157 non-SCLC in nude mice

European Journal of Cancer

Volumn 37, Issue 5, 2001, Pages 620-628

  Kiaris, H ^a,b   Schally, A V ^a,b   Nagy, A ^a,b   Szepeshazi, K ^a,b   Hebert, F ^a   Halmos, G ^a,b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Chemotherapy; Doxorubicin; Lung cancer; Receptor; Targeted analogue; Tumour inhibition

Indexed keywords

2 PYRROLINODOXORUBICIN; CYTOTOXIC AGENT; DEXTRO PHENYLALANYLCYSTEINYLTYROSYL DEXTRO TRYPTOPHYLLYSYLVALYLCYSTEINYLTHREONINAMIDE 2,7 DISULFIDE; DEXTRO PHENYLALANYLCYSTEINYLTYROSYL DEXTRO TRYPTOPHYLLYSYLVALYLCYSTEINYLTHREONINAMIDE 2,7 DISULFIDE 2 PYRROLINODOXORUBICIN; MESSENGER RNA; SOMATOSTATIN DERIVATIVE; SOMATOSTATIN RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; BINDING AFFINITY; BINDING SITE; CANCER GROWTH; CANCER INHIBITION; CONTROLLED STUDY; DOSE RESPONSE; DRUG POTENCY; GROWTH RATE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; MALE; MOUSE; NECROSIS; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; RECEPTOR BINDING; TUMOR VOLUME; XENOGRAFT;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SMALL CELL; CELL DIVISION; DOXORUBICIN; LUNG NEOPLASMS; MALE; MICE; MICE, NUDE; PYRROLES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER;

EID: 0035094324     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(00)00437-8     Document Type: Article

References (37)

1. Small cell lung cancer
2. Cancer mortality in Europe, 1990-1994, and an overview of trends from 1955 to 1994
3. Chemotherapy targeted to hormone receptors on tumours
4. Recombinant toxins for cancer treatment
5. Synthesis and biological evaluation of cytotoxic analogues of Somatostatin containing doxorubicin or its intensely potent derivative, 2-pyrrolinodoxorubicin
6. High-yield conversion of doxorubicin to 2-pyrrolinodoxorubicin, an analogue 500-1000 times more potent: Structure-activity relationship of daunosamine-modified derivatives of doxorubicin
7. Targeted cytotoxic analogue of Somatostatin AN-238 inhibits growth of androgen-independent Dunning R-3327-AT-1 prostate cancer in rats at nontoxic doses
8. Inhibition of PC-3 human androgen-independent prostate cancer and its metastases by cytotoxic somatostatin analogue AN-238
9. Inhibition of growth of MX-1, MCF-7-MIII and MDA-MB-231 human breast cancers after administration of targeted cytotoxic analogue of somatostatin, AN-238
10. Regression of U-87MG human glioblastomas in nude mice after treatment with a cytotoxic somatostatin analogue AN-238
11. Inhibition of metastatic renal cell carcinomas expressing Somatostatin receptors by a targeted cytotoxic analogue of Somatostatin AN-238
12. Somatostatin receptors are present in small-cell but not in non-small-cell primary lung carcinomas: Relationship to EGF receptors
13. Identification of somatostatin receptors in human small cell lung carcinoma
14. Experimental and clinical studies with Somatostatin analog octreotide in small cell lung cancer
15. Somatostatin receptor expression in lung cancer
16. Effects of Somatostatin analog RC-160 and bombesin/gastrin releasing peptide antagonists on the growth of human small-cell and non-small-cell lung carcinomas in nude mice
17. The value of octreotide scintigraphy in patients with lung cancer
18. Imaging of non-small-cell lung cancer with indium-111 pentetreotide
19. Expression of somatostatin receptors in peritumoural veins of human tumours
20. Growth inhibition of estrogen independent MXT mouse mammary carcinomas in mice treated with an agonist or antagonist of LHRH, an analogue of Somatostatin or a combination
21. Improved silver technique for showing nuclear organizer regions in paraffin wax sections
22. Decrease in the AgNOR number in Dunning R3327 prostate cancers after treatment with agonists and antagonists of luteinizing hormone-releasing hormone
23. Ligand: A versatile computerized approach for characterization of ligand binding systems
24. Expression of somatostatin receptor (SSTR) subtypes in pituitary adenomas: Quantitative analysis of SSTR2 mRNA by reverse transcription-polymerase chain reaction
25. Human ovarian cancers express somatostatin receptors
26. Somatostatin receptor subtypes sst1 and sst2 elicit opposite effects on the response of mouse hypothalamic neurons: An electrophysiological and single cell RT-PCR study
27. Insulin secretion is inhibited by subtype five somatostatin receptor in the mouse
28. Quantitation of mouse and rat B-actin mRNA by competitive polymerase chain reaction using capillary electrophoresis
29. Stability of cytotoxic luteinizing hormone-releasing hormone conjugate (AN-152) containing doxorubicin 14-O-hemiglutarate in mouse and human serum in vitro: Implications for the design of preclinical studies
30. Apoptosis versus necrosis: Which should be the aim of the cancer therapy?
31. Localization of small-cell lung cancer xenografts with iodine-125, indium-111, and rhenium-188-somatostatin analogues
32. Somatostatin analogues and lung cancer
33. Somatostatin and the immune and haemapoetic system; a review
34. Somatostatin receptor subtype gene expression in human and rodent tumours
35. Production of gastrin-releasing peptide by a non-small cell lung carcinoma cell line adapted to serum-free and growth factor-free conditions
36. Somatostatin controls Kaposi's sarcoma tumour growth through inhibition of angiogenesis
37. Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model